Sunday, December 28, 2025 | 09:25 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Sohini Das

Sohini Das

Sohini Das

Sohini Das leads the automobile and healthcare verticals at Business Standard. In her 17 years as a journalist, she has written on myriad subjects and sectors -- FMCG, dairies, tourism, and state elections, among others, across Kolkata, Ahmedabad and now Mumbai. She loves doing personality stories and ground reportage.

Sohini Das leads the automobile and healthcare verticals at Business Standard. In her 17 years as a journalist, she has written on myriad subjects and sectors -- FMCG, dairies, tourism, and state elections, among others, across Kolkata, Ahmedabad and now Mumbai. She loves doing personality stories and ground reportage.

Email
Twitter
LinkedIn

Page 59 - Sohini Das

Medical tourism is set to beat pre-Covid-19 levels in next two quarters

Meanwhile, traditional Indian medicine centers have once again started receiving patients from overseas

Medical tourism is set to beat pre-Covid-19 levels in next two quarters
Updated On : 30 Aug 2022 | 12:22 AM IST

Pricing regulator closely watching prices of diabetes drug going off patent

Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations

Pricing regulator closely watching prices of diabetes drug going off patent
Updated On : 28 Aug 2022 | 11:59 PM IST

Clear spike in heart attack cases after Covid-19 outbreak, say doctors

In recent times, several young celebrities, from politics to music to films, have succumbed to sudden heart attacks

Clear spike in heart attack cases after Covid-19 outbreak, say doctors
Updated On : 26 Aug 2022 | 12:00 AM IST

Rise of cosmetic dermatology space gets big pharma looking for buyouts

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Rise of cosmetic dermatology space gets big pharma looking for buyouts
Updated On : 26 Aug 2022 | 6:10 AM IST

Bayer brings kidney disease treatment drug to India at 1/15th US cost

Brand named Kerendia (finerenone) will cost Rs 97.5 per day as treatment cost in India

Bayer brings kidney disease treatment drug to India at 1/15th US cost
Updated On : 25 Aug 2022 | 7:46 PM IST

After Covid, now a mammoth vaccination drive for lumpy skin disease

Cattle are being vaccinated swiftly as the disease breaks out of its initial holds of Rajasthan and Gujarat and starts infecting buffaloes too

After Covid, now a mammoth vaccination drive for lumpy skin disease
Updated On : 24 Aug 2022 | 3:17 AM IST

Dolo 650 maker says drug part of Covid treatment, denies 'freebie' charges

In paracetamol market, Dolo's share rose to 24% from 15% pre-Covid-19

Dolo 650 maker says drug part of Covid treatment, denies 'freebie' charges
Updated On : 23 Aug 2022 | 12:23 AM IST

Ethical Code to keep doctor, drugmaker nexus at bay not mandatory yet

The recent controversy following income tax raids on Micro Labs, makers of popular paracetamol brand Dolo, is likely to make things move in making the UCPMP

Ethical Code to keep doctor, drugmaker nexus at bay not mandatory yet
Updated On : 21 Aug 2022 | 11:57 PM IST

PharmEasy calls off its public offer; to go for rights issue instead

API Holdings, the parent company of PharmEasy, wrote to shareholders announcing withdrawal of DRHP

PharmEasy calls off its public offer; to go for rights issue instead
Updated On : 20 Aug 2022 | 9:09 PM IST
The pink of health: Trade generics now key growth driver for Cipla
Updated On : 20 Aug 2022 | 5:48 PM IST

Centre proposes anti-dumping duty on China antibiotic drug ofloxacin

No impact on end consumer as prices are regulated

Centre proposes anti-dumping duty on China antibiotic drug ofloxacin
Updated On : 20 Aug 2022 | 12:52 AM IST

US ranitidine litigation unlikely to impact Indian pharma: Analysts

Sun Pharmaceuticals, Dr Reddy's Laboratories, Perrigo and Teva have agreed to a combined settlement of $5 mn with cancer patient Joseph Bayer

US ranitidine litigation unlikely to impact Indian pharma: Analysts
Updated On : 19 Aug 2022 | 11:09 PM IST

Serum Institute, other firms eye tie-ups to develop monkeypox vaccine

Indian Immunologicals, and Haffkine Research Institute also in the fray

Serum Institute, other firms eye tie-ups to develop monkeypox vaccine
Updated On : 18 Aug 2022 | 10:01 PM IST

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025
Updated On : 18 Aug 2022 | 12:51 AM IST

SII may use Oxford Biomedica's plant to make malaria, flu vaccines

SII is building a future pandemic facility, which will have an annual capacity of 2 bn doses

SII may use Oxford Biomedica's plant to make malaria, flu vaccines
Updated On : 16 Aug 2022 | 12:04 AM IST

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

Seeks nod as both primary and precaution dose

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'
Updated On : 15 Aug 2022 | 11:10 PM IST

Indian Covid vaccine makers eye regulator nod for universal boosters

Plans afoot to seek regulator nod for universal boosters

Indian Covid vaccine makers eye regulator nod for universal boosters
Updated On : 12 Aug 2022 | 12:33 AM IST

Mandatory mask rule, fines back in Delhi as Covid cases rise again

Sharp rise in test positivity rate in Delhi past few weeks; doctors say many admitted for other ailments testing Covid-positive; Mumbai also sees spurt in cases

Mandatory mask rule, fines back in Delhi as Covid cases rise again
Updated On : 11 Aug 2022 | 10:12 PM IST

Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore

Adjusted Ebidta was Rs 4,72.6 crore in the quarter ended June 30, 2022 as against Rs 5,73.6 crore in the previous corresponding quarter, with margins of 17 per cent

Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore
Updated On : 10 Aug 2022 | 11:49 PM IST

Biological E's Corbevax gets a boost, as govt allows mixing vaccines

Health ministry nod to the Biological E vaccine as 3rd dose after Covishield or Covaxin, CoWIN to be updated within a week

Biological E's Corbevax gets a boost, as govt allows mixing vaccines
Updated On : 10 Aug 2022 | 9:19 PM IST